Do inhaled corticosteroids protect against lung cancer in patients with COPD? A systematic review

Respirology

Volumn 22, Issue 1, 2017, Pages 61-70

  Raymakers, Adam J N ^a   McCormick, Natalie ^a   Marra, Carlo A ^b   Fitzgerald, J Mark ^a   Sin, Don ^a   Lynd, Larry D ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

chronic obstructive pulmonary disease; drug utilization; inhaled corticosteroids; lung cancer; review

Indexed keywords

BRONCHODILATING AGENT; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; LONG ACTING DRUG; PLACEBO; SALMETEROL; SHORT ACTING DRUG; TRIAMCINOLONE; GLUCOCORTICOID;

CANCER PREVENTION; CANCER RISK; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG EFFICACY; DRUG EXPOSURE; HUMAN; LUNG CANCER; MONOTHERAPY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; INHALATIONAL DRUG ADMINISTRATION; LUNG TUMOR; PATIENT ACUITY; RISK ASSESSMENT;

ADMINISTRATION, INHALATION; GLUCOCORTICOIDS; HUMANS; LUNG NEOPLASMS; PATIENT ACUITY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK ASSESSMENT;

EID: 84991824734     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.12919     Document Type: Review

References (36)

1. Raherison C, Girodet P-O. Epidemiology of COPD. Eur. Respir. Rev. 2009; 18: 213–21.
2. Young RP, Hopkins RJ, Christmas T, Black PN, Metcalf P, Gamble GD. COPD prevalence is increased in lung cancer, independent of age, sex and smoking history. Eur. Respir. J. 2009; 34: 380–6.
3. Lundbäck B, Lindberg A, Lindström M, Rönmark E, Jonsson AC, Jönsson E, Larsson LG, Andersson S, Sandström T, Larsson K; Obstructive Lung disease in northern Sweden Studies. Not 15 but 50% of smokers develop COPD? Report from the Obstructive Lung Disease in Northern Sweden Studies. Respir. Med. 2003; 97: 115–22.
4. Løkke A, Lange P, Scharling H, Fabricius P, Vestbo J. Developing COPD: a 25 year follow up study of the general population. Thorax 2006; 61: 935–9.
5. Vestbo J, Lange P. Natural history of COPD: focusing on change in FEV: natural history of COPD. Respirology 2016; 21: 34–43.
6. Tan WC, Sin DD, Bourbeau J, Hernandez P, Chapman KR, Cowie R, FitzGerald JM, Marciniuk DD, Maltais F, Buist AS et al.; CanCOLD Collaborative Research Group. Characteristics of COPD in never-smokers and ever-smokers in the general population: results from the CanCOLD study. Thorax 2015; 70: 822–9.
7. Ford ES, Murphy LB, Khavjou O, Giles WH, Holt JB, Croft JB. Total and state-specific medical and absenteeism costs of chronic obstructive pulmonary disease among adults aged ≥18 years in the United States for 2010 and projections through 2020. Chest 2015; 147: 31–45.
8. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997; 349: 1498–504.
9. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J. Clin. 2015; 65: 87–108.
10. Fry JS, Hamling JS, Lee PN. Systematic review with meta-analysis of the epidemiological evidence relating FEV1 decline to lung cancer risk. BMC Cancer 2012; 12: 498.
11. Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers--a different disease. Nat. Rev. Cancer 2007; 7: 778–90.
12. Mannino DM, Aguayo SM, Petty TL, Redd SC. Low lung function and incident lung cancer in the United States: data from the first National Health and Nutrition Examination Survey follow-up. Arch. Intern. Med. 2003; 163: 1475–80.
13. Turner MC, Chen Y, Krewski D, Calle EE, Thun MJ. Chronic obstructive pulmonary disease is associated with lung cancer mortality in a prospective study of never smokers. Am. J. Respir. Crit. Care Med. 2007; 176: 285–90.
14. Purdue MP, Gold L, Järvholm B, Alavanja MCR, Ward MH, Vermeulen R. Impaired lung function and lung cancer incidence in a cohort of Swedish construction workers. Thorax 2007; 62: 51–6.
15. Skillrud DM, Offord KP, Miller RD. Higher risk of lung cancer in chronic obstructive pulmonary disease. A prospective, matched, controlled study. Ann. Intern. Med. 1986; 105: 503–7.
16. Van Eeden S, Leipsic J, Paul Man SF, Sin DD. The relationship between lung inflammation and cardiovascular disease. Am. J. Respir. Crit. Care Med. 2012; 186: 11–6.
17. Wasswa-Kintu S, Gan WQ, Man SFP, Pare PD, Sin DD. Relationship between reduced forced expiratory volume in one second and the risk of lung cancer: a systematic review and meta-analysis. Thorax 2005; 60: 570–5.
18. Global Initiative for Chronic Obstructive Lung Disease (GOLD). GOLD - the Global Initiative for Chronic Obstructive Lung Disease, 2013. [Accessed 21 Feb 2016.] Available from URL: http://goldcopd.org/global-strategy-diagnosis-management-prevention-copd-2016/.
19. Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabedian S, Peterson S, Olsson H. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur. Respir. J. 2003; 21: 74–81.
20. Calverley PMA, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 2007; 356: 775–89.
21. Gartlehner G, Hansen RA, Carson SS, Lohr KN. Efficacy and safety of inhaled corticosteroids in patients with COPD: a systematic review and meta-analysis of health outcomes. Ann. Fam. Med. 2006; 4: 253–62.
22. Yang IA, Clarke MS, Sim EHA, Fong KM. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2012; 7: CD002991.
23. Sin DD, Wu L, Anderson JA, Anthonisen NR, Buist AS, Burge PS, Calverley PM, Connett JE, Lindmark B, Pauwels RA et al. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax 2005; 60: 992–7.
24. Suissa S, Patenaude V, Lapi F, Ernst P. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax 2013; 68: 1029–36.
25. Sin DD, Lacy P, York E, Man SF. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2004; 170: 760–5.
26. Kiri VA, Fabbri LM, Davis KJ, Soriano JB. Inhaled corticosteroids and risk of lung cancer among COPD patients who quit smoking. Respir. Med. 2009; 103: 85–90.
27. Lung Health Study Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N. Engl. J. Med. 2000; 343: 1902–9.
28. Parimon T, Chien JW, Bryson CL, McDonell MB, Udris EM, Au DH. Inhaled corticosteroids and risk of lung cancer among patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2007; 175: 712–9.
29. Pauwels RA, Löfdahl C-G, Laitinen LA, Schouten JP, Postma DS, Pride NB, Ohlsson SV. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N. Engl. J. Med. 1999; 340: 1948–53.
30. Tashkin DP, Rennard SI, Martin P, Ramachandran S, Martin UJ, Silkoff PE, Goldman M. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease. Drugs 2008; 68: 1975–2000.
31. Ryan R. Heterogeneity and subgroup analyses in Cochrane Consumers and Communication Review Group reviews: planning the analysis at protocol stage. Cochrane Consumers and Communication Review Group, 2014. [Accessed 23 June 2016.] Available from URL: http://cccrg.cochrane.org/sites/cccrg.cochrane.org/files/public/uploads/Heterogeneity_subgroup_analyses_0.pdf.
32. Edwards DJG, Anderson I. Systematic review and guide to selection of selective serotonin reuptake inhibitors. Drugs 1999; 57: 507–33.
33. Higgins J, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2011. [Accessed 29 June 2016.] Available from URL: http://handbook.cochrane.org/.
34. Delgado-Rodríguez M, Llorca J. Bias. J. Epidemiol. Community Health 2004; 58: 635–41.
35. Lee C-H, Hyun MK, Jang EJ, Lee NR, Kim K, Yim J-J. Inhaled corticosteroid use and risks of lung cancer and laryngeal cancer. Respir. Med. 2013; 107: 1222–33.
36. Kiri VA, Soriano J, Visick G, Fabbri L. Recent trends in lung cancer and its association with COPD: an analysis using the UK GP Research Database. Prim. Care Respir. J. 2010; 19: 57–61.